PLG antibody (AA 251-350)

Catalog No. ABIN735038

Product Details anti-PLG Antibody

Target: PLG (Plasminogen (PLG))

Binding Specificity: AA 251-350

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This PLG antibody is un-conjugated

Application: Western Blotting (WB), ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Cross-Reactivity: Human

Predicted Reactivity: Mouse,Rat,Dog,Cow,Pig

Purification: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human PLG

Isotype: IgG

Application Details

Application Notes: WB 1:300-5000
ELISA 1:500-1000
IHC-P 1:200-400

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 μg/μL

Buffer: 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Expiry Date: 12 months

Target Details for PLG

Target: PLG (Plasminogen (PLG))

Alternative Name: Plasminogen (PLG Products)

Synonyms: wu:fb70e09 antibody, PLG antibody, LPA antibody, plg antibody, Ab1-346 antibody, AI649309 antibody, Pg antibody, plasminogen antibody, plg antibody, PLG antibody, Plg antibody

Background:

Synonyms: Plasminogen, Angiostatin, DKFZp779M0222, Microplasmin, Plasmin, Plasmin heavy chain A, PLG, PLMN_HUMAN.

Background: Plasminogen is a plasma protein synthesised mostly in the liver. Plasma concentration is usually in the range of 70 to 200 mg/l. Plasminogen is activated by tissue plasminogen activator, urokinase and streptokinase, to form plasmin. Activation results from the cleavage and release of the preactivation peptide. Angiostatin, an internal fragment of plasminogen, is a potent inhibitor of angiogenesis, which selectively inhibits endothelial cell proliferation. Angiostatin potently inhibits tumor growth and can maintain metastatic and primary tumors in a dormant state. It is defined by a balance of proliferation and apoptosis of the tumor cells and is composed of plasminogen first four cringle structures. This molecule is generated by proteolytic cleavage of plasminogen.

Gene ID: 5340

UniProt: P00747

Pathways: Complement System, Lipid Metabolism